Scientists have created a strain of E. coli bacteria with a significantly streamlined genetic code, demonstrating that life can function with fewer than the standard 64 codons.
Why it matters: This groundbreaking achievement opens new possibilities for biotechnology and medicine, such as engineering bacteria resistant to viral infections and expanding the genetic code to create synthetic proteins with novel capabilities.
The details:
- The new strain, named Syn57, operates with just 57 codons, eliminating redundant codons without compromising viability.
- The project involved meticulously recoding over 101,000 codons in a 4 Mb synthetic genome.
- The genome was divided into 38 fragments, synthesized using homologous recombination in yeast, and inserted using an advanced method called uREXER.
- Throughout the process, the team addressed challenges related to resistant genome regions and growth rate stunting.
The research team, led by Wes Robertson, Fabian Rehm, Martin Spinck, Raffael Schumann, and Rongzhen Tian at the MRC Laboratory of Molecular Biology, employed various strategies to overcome obstacles, including optimizing gene expression and tweaking codon swaps.
The potential:
- Syn57 provides a valuable platform for introducing non-canonical amino acids, potentially broadening the genetic code for new synthetic polymers and macrocycles.
- The strain could be engineered to be resistant to viral infections by ensuring it cannot read the canonical genetic code, offering a promising avenue for more stable and cost-effective drug manufacturing.
The reaction: “This is a significant achievement and the result of years of work,” comments a researcher from Harvard Medical School, whose team is also working on their own 57-codon strain.
What’s next: While Syn57 is complete, its growth rate needs improvement for commercial viability. The focus will be on exploring its potential applications rather than further compressing the genetic code.
This achievement marks a significant milestone in synthetic biology, setting the stage for future innovations and advancements in science and medicine.
